[go: up one dir, main page]

BR0015061A - Núcleo de comprimido de polìmero por compressão direta - Google Patents

Núcleo de comprimido de polìmero por compressão direta

Info

Publication number
BR0015061A
BR0015061A BR0015061-4A BR0015061A BR0015061A BR 0015061 A BR0015061 A BR 0015061A BR 0015061 A BR0015061 A BR 0015061A BR 0015061 A BR0015061 A BR 0015061A
Authority
BR
Brazil
Prior art keywords
tablet core
polymer
aliphatic amine
core
amine polymer
Prior art date
Application number
BR0015061-4A
Other languages
English (en)
Other versions
BRPI0015061B8 (pt
BRPI0015061B1 (pt
Inventor
Joseph Tyler
John S Petersen
Original Assignee
Geltex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geltex Pharma Inc filed Critical Geltex Pharma Inc
Publication of BR0015061A publication Critical patent/BR0015061A/pt
Publication of BRPI0015061B1 publication Critical patent/BRPI0015061B1/pt
Publication of BRPI0015061B8 publication Critical patent/BRPI0015061B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"NúCLEO DE COMPRIMIDO DE POLìMERO POR COMPRESSãO DIRETA". A presente invenção provê um núcleo de comprimido que compreende pelo menos cerca de 95% em peso de um polímero de amina alifática. A invenção também provê um método para produzir um núcleo de comprimido compreendendo pelo menos cerca de 95% em peso de uma resina de polímero de amina alifática. O método compreende a etapa de comprimir o polímero de amina alifática para formar o núcleo de comprimido. O núcleo de comprimido pode adicionalmente incluir um ou mais excipientes. Nesta configuração, o método para produzir o núcleo de comprimido compreende as etapas de: (1) hidratar o polímero de amina alifática até o nível de umidade desejado; (2) misturar o polímero de amina alifática com os excipientes em quantidades tais que o polímero compreenda pelo menos cerca de 95% em peso da mistura resultante; e (3) comprimir a mistura para formar o núcleo de comprimido. A presente invenção adicionalmente relaciona-se com um comprimido revestido compreendendo um núcleo de polímero de amina alifática onde o revestimento é um revestimento baseado em água.
BRPI0015061A 1999-10-19 2000-10-13 comprimido revestido tendo alta dosagem de cloridrato de sevelamer BRPI0015061B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16025899P 1999-10-19 1999-10-19
US17422700P 2000-01-03 2000-01-03
PCT/US2000/028548 WO2001028527A2 (en) 1999-10-19 2000-10-13 Direct compression polymer tablet core

Publications (3)

Publication Number Publication Date
BR0015061A true BR0015061A (pt) 2002-07-23
BRPI0015061B1 BRPI0015061B1 (pt) 2016-03-22
BRPI0015061B8 BRPI0015061B8 (pt) 2021-05-25

Family

ID=26856737

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0015061A BRPI0015061B8 (pt) 1999-10-19 2000-10-13 comprimido revestido tendo alta dosagem de cloridrato de sevelamer

Country Status (29)

Country Link
EP (1) EP1239837B1 (pt)
JP (4) JP4942271B2 (pt)
KR (1) KR100794427B1 (pt)
CN (1) CN1202812C (pt)
AR (1) AR026067A1 (pt)
AT (1) ATE286386T1 (pt)
AU (1) AU778262B2 (pt)
BG (1) BG106626A (pt)
BR (1) BRPI0015061B8 (pt)
CA (1) CA2387915C (pt)
CZ (1) CZ20021344A3 (pt)
DE (1) DE60017285T2 (pt)
EA (1) EA200200387A1 (pt)
EE (1) EE200200209A (pt)
ES (1) ES2235969T3 (pt)
HK (1) HK1049451B (pt)
HU (1) HUP0203334A2 (pt)
IL (1) IL149146A0 (pt)
IS (1) IS6343A (pt)
MX (1) MXPA02003684A (pt)
MY (1) MY125495A (pt)
NO (1) NO20021827L (pt)
NZ (1) NZ518334A (pt)
PL (1) PL364888A1 (pt)
PT (1) PT1239837E (pt)
SK (1) SK5412002A3 (pt)
TR (1) TR200201087T2 (pt)
TW (1) TWI225413B (pt)
WO (1) WO2001028527A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518334A (en) * 1999-10-19 2003-08-29 Genzyme Corp Direct compression polymer tablet core
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
CA2551528A1 (en) * 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
DE602005019992D1 (de) 2004-03-30 2010-04-29 Relypsa Inc Kaliumbindende polymere und ihre verwendungen
US7985418B2 (en) * 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
AU2012200480B2 (en) * 2004-11-01 2014-10-16 Genzyme Corporation "Aliphatic amine polymer salts for tableting"
BRPI0609524A2 (pt) * 2005-03-17 2011-10-18 Amgen Inc uso de uma quantidade terapeuticamente eficaz de um composto calcimimético
US8986669B2 (en) 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
KR101547925B1 (ko) * 2005-09-15 2015-08-27 젠자임 코포레이션 아민 중합체에 대한 샤셋 제형
BRPI0717008A2 (pt) * 2006-09-01 2014-01-21 Usv Ltd Processo para o preparo de cloridrato de sevelamer e formulação do mesmo
WO2008042222A2 (en) 2006-09-29 2008-04-10 Genzyme Corporation Amide dendrimer compositions
EP2120972A1 (en) 2006-12-14 2009-11-25 Genzyme Corporation Amido-amine polymer compositions
WO2009034540A1 (en) * 2007-09-11 2009-03-19 Ranbaxy Laboratories Limited Pharmaceutical composition of sevelamer
DE102008030046A1 (de) * 2008-06-25 2009-12-31 Ratiopharm Gmbh Kompaktiertes Polyallylamin-Polymer
US20110159087A1 (en) 2008-09-02 2011-06-30 Dhananjay Govind Sathe Crosslinked Polymers
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
ES2350999B1 (es) * 2009-06-26 2011-12-07 Combino Pharm, S.L. Nueva composición farmacéutica comprendiendo hidrocloruro de poli (alilamin-co-n,n'-dialil-1,3-diamino-2-hidroxi propano).
WO2010149794A2 (en) 2009-06-26 2010-12-29 Combino Pharm, S.L. Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane)
US20120219626A1 (en) * 2009-10-22 2012-08-30 Niels Jaap Osinga Pharmaceutical Compositions of Sevelamer
EP2545907A1 (en) 2011-07-15 2013-01-16 Combino Pharm, S.L. Aqueous wet granulation process for cross-linked polyallylamine polymers
US9693962B2 (en) * 2012-06-05 2017-07-04 Takeda Pharmaceutical Limited Dry-coated tablet
CN102908325B (zh) * 2012-11-12 2014-07-30 南京生命能科技开发有限公司 一种碳酸司维拉姆药用片剂组合物及其制备方法
CN107412166B (zh) * 2017-08-08 2020-03-24 同济大学 一种纳米复合吸附磷材料及其制备与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL169045B1 (pl) * 1991-07-03 1996-05-31 Upjohn Co Sposób wytwarzania tabletki farmaceutycznej do leczenia lub zapobiegania hipercholesterolemii PL
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
TW592727B (en) * 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
JP3389493B2 (ja) * 1997-04-04 2003-03-24 中外製薬株式会社 リン酸結合性ポリマー製剤
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
TW568788B (en) * 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
NZ518334A (en) * 1999-10-19 2003-08-29 Genzyme Corp Direct compression polymer tablet core

Also Published As

Publication number Publication date
NO20021827D0 (no) 2002-04-18
HUP0203334A2 (hu) 2003-02-28
EP1239837B1 (en) 2005-01-05
TR200201087T2 (tr) 2002-08-21
TWI225413B (en) 2004-12-21
ES2235969T3 (es) 2005-07-16
MXPA02003684A (es) 2002-08-30
AU1088701A (en) 2001-04-30
BRPI0015061B8 (pt) 2021-05-25
EA200200387A1 (ru) 2002-10-31
PT1239837E (pt) 2005-05-31
CN1382041A (zh) 2002-11-27
NO20021827L (no) 2002-05-29
KR100794427B1 (ko) 2008-01-16
EP1239837A2 (en) 2002-09-18
AR026067A1 (es) 2002-12-26
WO2001028527A3 (en) 2002-01-03
CN1202812C (zh) 2005-05-25
BRPI0015061B1 (pt) 2016-03-22
MY125495A (en) 2006-08-30
JP5903111B2 (ja) 2016-04-13
CZ20021344A3 (cs) 2002-08-14
DE60017285D1 (de) 2005-02-10
CA2387915C (en) 2007-04-17
SK5412002A3 (en) 2002-09-10
JP2012067132A (ja) 2012-04-05
WO2001028527A2 (en) 2001-04-26
JP2003512317A (ja) 2003-04-02
JP4942271B2 (ja) 2012-05-30
BG106626A (bg) 2003-03-31
DE60017285T2 (de) 2005-12-08
JP5583110B2 (ja) 2014-09-03
JP2014065749A (ja) 2014-04-17
CA2387915A1 (en) 2001-04-26
IL149146A0 (en) 2002-11-10
HK1049451A1 (en) 2003-05-16
PL364888A1 (en) 2004-12-27
AU778262B2 (en) 2004-11-25
ATE286386T1 (de) 2005-01-15
JP2016000753A (ja) 2016-01-07
NZ518334A (en) 2003-08-29
KR20020059629A (ko) 2002-07-13
IS6343A (is) 2002-04-15
HK1049451B (zh) 2005-12-16
EE200200209A (et) 2003-06-16

Similar Documents

Publication Publication Date Title
BR0015061A (pt) Núcleo de comprimido de polìmero por compressão direta
BRPI0316532B8 (pt) composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável
BR0312464A (pt) Inibidores de tirosina quinases
ES2061252T3 (es) Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
BR0107535A (pt) Uso de carotenóides e forma de dosagem unitária destes
WO2004010941A3 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
DE60036874D1 (de) Pellet formulierung mit gesteuerter freisetzung
KR850007559A (ko) 조절 펩타이드의 삽입식 제형
BR0315115A (pt) Compostos, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios em que se requer um antagonista de receptores de orexina humana, processo para a fabricação de composições farmacêuticas, e, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
DE59913682D1 (de) Verfahren zur Herstellung von festen Dosierungsformen
DE122004000032I1 (de) Zusammensetzung, die eine tramadol-verbindung und Acetainophen enth{lt, und ihre verwendung.
BG101901A (bg) 2-метил-тиено-бензодиазепинова формулировка за приемане през устата и метод за нейното получаване
BRPI0619572B8 (pt) método para a preparação de um carbonato de cálcio revestido com película, método para a preparação de tablete farmacêutico ou nutricional compreendendo um carbonato de cálcio revestido com película, carbonato de cálcio revestido com película e composição farmacêutica ou nutricional
BR0114368A (pt) Processo para preparar um elastÈmero de poliuréia, e, elastÈmero de poliuréia
BR0010569A (pt) Método para produção de uma pasta de dentes
PT1158962E (pt) Processo para a preparacao de formas de dosagem solidas que contem ciclodextrina
BR0207827A (pt) Método de preparação de uma micropartìcula homogênea que compreende um inibidor de h+/k+-atpase ácido lábil, micropartìcula, composição farmacêutica, método para prevenir ou tratar uma doença relacionada com o ácido gástrico em um mamìfero, e, uso de uma micropartìcula
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
ES2120145T3 (es) Compuestos bi-aromaticos acetilenados con grupo adamantilo, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
BR0317452A (pt) Métodos para revestimento de substratos para usos farmacêuticos com uma mistura de dois agentes de revestimento formadores de pelìculas
BR0302680A (pt) Dispositivo oftálmico contendo compostos heterocìclicos e métodos para produção dos mesmos
ATE444739T1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
BR9811515A (pt) Composição de revestimento curável através de radiação
MXPA05010102A (es) Trihidrato de amoxicilina.
BRPI0412850A (pt) misturas de oligossacarìdeos derivados de heparina, o respectivo preparo e as composições farmacêuticas que as contêm

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GENZYME CORPORATION (US)

Free format text: TRANSFERIDO DE: GELTEX PHARMACEUTICALS, INC.

B25G Requested change of headquarter approved

Owner name: GENZYME CORPORATION (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080029522/SP DE 14/05/2008.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 9/20

Ipc: A61K 31/785 (2009.01), A61K 9/28 (2009.01), A61K 3

B15V Prolongation of time limit allowed

Free format text: DEVOLUCAO DE PRAZO CONCEDIDA - RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 19 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/03/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13/10/2020